Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10

Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10

Chemo-immunotherapy is central to the treatment of small cell lung cancer (SCLC). Despite modest progress made with the addition of immunotherapy, current cytotoxic regimens display minimal survival benefit and new treatments are needed. Thymidylate synthase (TS) is a well-validated anti-cancer drug...

Full description

Bibliographic Details
Main Authors: William H. Gmeiner, Lance D. Miller, Jeff W. Chou, Anthony Dominijanni, Lysette Mutkus, Frank Marini, Jimmy Ruiz, Travis Dotson, Karl W. Thomas, Graham Parks, Christina R. Bellinger
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
sclc
rna-seq
patient-derived organoid
thymidylate synthase
fluoropyrimidine
Online Access:https://www.mdpi.com/2072-6694/12/4/788

Internet

https://www.mdpi.com/2072-6694/12/4/788

Similar Items